The future may involve: Sequencing and Combination: Using agents with complementary mechanisms (e.g., an incretin for weight loss combined with a myostatin inhibitor for lean mass preservation)
Millions of people with Medicare and Medicaid could benefit from expanded coverage of GLP-1s for obesity Overall, CMSs efforts to expand Medicare and Medicaid coverage of GLP-1s for people with Medicare and Medicaid could greatly expand access to these drugs, albeit on a temporary basis, depending on the level of participation by drug manufacturers, state Medicaid agencies and Part D plans
J Clin Med
Your team identified and characterized the market participants as well as underlying trends accurately
For the first 2.5 h post-dosing, mean ICP was calculated from each 30 min of continuous ICP monitoring
the goal is to improve health, reduce risk, preserve strength, and maintain results